Search Results - "Smirnakis, Karen"

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels: Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins by DIAS, Clapton S, SHAYWITZ, Adam J, GIBBS, John P, RETTER, Marc W, COOKE, Blaire P, UY, Stephen T, MATSON, Mark, STEIN, Evan A, WASSERMAN, Scott M, SMITH, Brian P, BING GAO, STOLMAN, Dina S, CRISPINO, Caroline P, SMIRNAKIS, Karen V, EMERY, Maurice G, COLBERT, Alexander

“…The aim of this study was to evaluate the safety, tolerability, and effects of AMG 145 on low-density lipoprotein cholesterol (LDL-C) in healthy and…”
Get full text

Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients by Danese, Mark D, Belozeroff, Vasily, Smirnakis, Karen, Rothman, Kenneth J

“…In 2003, the National Kidney Foundation introduced guidelines for the control of parathyroid hormone, calcium, and phosphorus in hemodialysis patients. A…”
Get full text

Predicting gestational diabetes: choosing the optimal early serum marker by Smirnakis, Karen V., MD, PhD, MPH, Plati, Alicia, MPH, Wolf, Myles, MS, MMSc, Thadhani, Ravi, MD, MPH, Ecker, Jeffrey L., MD

“…Objective Serum markers measured early in pregnancy have been associated with the later diagnosis of gestational diabetes mellitus. To select an optimal early…”
Get full text

Postpartum diabetes screening in women with a history of gestational diabetes by SMIRNAKIS, Karen V, CHASAN-TABER, Lisa, WOLF, Myles, MARKENSON, Glenn, ECKER, Jeffrey L, THADHANI, Ravi

“…Women with a history of gestational diabetes mellitus (GDM) are at high risk for developing type 2 diabetes (diabetes mellitus, DM). The American Diabetes…”
Get full text

Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies by Wolf, Myles, Shah, Anand, Lam, Chun, Martinez, Abelardo, Smirnakis, Karen V., Epstein, Franklin H., Taylor, Robert N., Ecker, Jeffrey L., Karumanchi, S. Ananth, Thadhani, Ravi

“…Preeclampsia is far more common in women's first pregnancy but the mechanism of this association is unknown. Altered angiogenesis, marked by increased levels…”
Get full text

Inflammation and glucose intolerance: A prospective study of gestational diabetes mellitus by WOLF, Myles, SAUK, Jenny, SHAH, Anand, SMIRNAKIS, Karen Vossen, JIMENEZ-KIMBLE, Ricardo, ECKER, Jeffrey L, THADHANI, Ravi

“…Increased leukocyte count is a marker of inflammation that has been associated with the development of type 2 diabetes in prospective studies. Although…”
Get full text

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels by Dias, Clapton S., PhD, Shaywitz, Adam J., MD, PhD, Wasserman, Scott M., MD, Smith, Brian P., PhD, Gao, Bing, PhD, Stolman, Dina S., MD, MSPH, Crispino, Caroline P., MS, Smirnakis, Karen V., MD, MPH, PhD, Emery, Maurice G., PhD, Colbert, Alexander, BA, Gibbs, John P., PhD, Retter, Marc W., PhD, Cooke, Blaire P., PharmD, Uy, Stephen T., MS, Matson, Mark, MD, Stein, Evan A., MD, PhD

“…Objectives The aim of this study was to evaluate the safety, tolerability, and effects of AMG 145 on low-density lipoprotein cholesterol (LDL-C) in healthy and…”
Get full text

Insulin Resistance and Alterations in Angiogenesis: Additive Insults That May Lead to Preeclampsia by Thadhani, Ravi, Ecker, Jeffrey L, Mutter, Walter P, Wolf, Myles, Smirnakis, Karen V, Sukhatme, Vikas P, Levine, Richard J, Karumanchi, S Ananth

“…ABSTRACT—Altered angiogenesis and insulin resistance, which are intimately related at a molecular level, characterize preeclampsia. To test if an…”
Get full text

First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes by Wolf, Myles, Sandler, Laura, Hsu, Karen, Vossen-Smirnakis, Karen, Ecker, Jeffrey L, Thadhani, Ravi

“…First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes Myles Wolf , MD, MMSC , Laura Sandler , BS , Karen Hsu , BA , Karen Vossen-Smirnakis ,…”
Get full text

Early Pregnancy Insulin Resistance and Subsequent Gestational Diabetes Mellitus by Smirnakis, Karen V, Martinez, Abelardo, Blatman, Karen Hsu, Wolf, Myles, Ecker, Jeffrey L, Thadhani, Ravi

“…Gestational diabetes mellitus, which complicates 3-7% of all pregnancies, is associated with increased maternal and fetal morbidity. With this, Smirnakis et al…”
Get full text

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease by Salloway, Stephen, Chalkias, Spyros, Barkhof, Frederik, Burkett, Patrick, Barakos, Jerome, Purcell, Derk, Suhy, Joyce, Forrestal, Fiona, Tian, Ying, Umans, Kimberly, Wang, Guanfang, Singhal, Priya, Budd Haeberlein, Samantha, Smirnakis, Karen

“…The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA)…”
Get more information

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies by Reder, Anthony T., Centonze, Diego, Naylor, Maria L., Nagpal, Anjali, Rajbhandari, Rajani, Altincatal, Arman, Kim, Michelle, Berdofe, Aaron, Radhakrishnan, Maha, Jung, Eunice, Sandrock, Alfred W., Smirnakis, Karen, Popescu, Catrinel, de Moor, Carl

“…Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute…”
Get full text

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing by Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R, Goldberg, Judith D, Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan

“…OBJECTIVETo use the large dataset from the Tysabri OutreachUnified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy…”
Get full text

Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P10-6.005) by Ryerson, Lana Zhovtis, Foley, John, Kister, Ilya, Cutter, Gary, Metzger, Ryan, Goldberg, Judith, Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Domingo-Horne, Rose, Lasky, Tyler

“…Abstract only…”
Get full text

Role of Hydration in the Binding of lac Repressor to DNA by Fried, Michael G., Stickle, Douglas F., Smirnakis, Karen Vossen, Adams, Claire, MacDonald, Douglas, Lu, Ponzy

“…The osmotic stress technique was used to measure changes in macromolecular hydration that accompany binding of wild-typeEscherichia coli lactose (lac)…”
Get full text

Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared With Every-4-Week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P13-4.010) by Ryerson, Lana Zhovtis, Foley, John, Kister, Ilya, Cutter, Gary, Metzger, Ryan, Goldberg, Judith D., Li, Xiaochun, Smirnakis, Karen, Dsilva, Liesel, Chin, Wai, Riddle, Evan

“…Abstract only…”
Get full text

Considerations for the Real-World Management of ARIA From the Aducanumab Phase 3 Studies EMERGE and ENGAGE (P1-1.Virtual) by Hughes, Richard, Burkett, Patrick, Chalkias, Spyridon, Umans, Kimberly, Castrillo-Viguera, Carmen, Purcell, Derk, Barakos, Jerome, Fam, Sami, Smirnakis, Karen, Haeberlein, Samantha Budd

“…Abstract only…”
Get full text

Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-Week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P14-3.011) by Ryerson, Lana Zhovtis, Foley, John, Kister, Ilya, Cutter, Gary, Metzger, Ryan, Goldberg, Judith, Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, DSilva, Liesel, Sinks, Susie, Campbell, Nolan, Lasky, Tyler, Bodhinathan, Karthik

“…Abstract only…”
Get full text

Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (4419) by Ryerson, Lana Zhovtis, Foley, John, Kister, Ilya, Cutter, Gary, Metzger, Ryan, Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Jin, Ling, Ren, Zheng, Campbell, Nolan

“…Abstract only…”
Get full text

Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6 - Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (S14.005) by Foley, John, Defer, Gilles, Ryerson, Lana Zhovtis, Cohen, Jeffrey A., Arnold, Doug L., Butzkueven, Helmut, Cutter, Gary, Giovannoni, Gavin, Killestein, Joep, Wiendl, Heinz, Smirnakis, Karen, Xiao, Shan, Kong, George, Kuhelj, Robert, Campbell, Nolan

“…Abstract only…”
Get full text